# Efficacy and Safety Profile of Remimazolam-alfentanil Combination for ERCP Sedation

> **NCT04658173** · NA · UNKNOWN · sponsor: **Tianjin Nankai Hospital** · enrollment: 1000 (estimated)

## Conditions studied

- Anesthesia

## Interventions

- **DRUG:** remimazolam-alfentanil combination
- **DRUG:** propofol-alfentanil combination

## Key facts

- **NCT ID:** NCT04658173
- **Lead sponsor:** Tianjin Nankai Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-22
- **Primary completion:** 2022-10-01
- **Final completion:** 2023-10-01
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2021-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04658173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04658173, "Efficacy and Safety Profile of Remimazolam-alfentanil Combination for ERCP Sedation". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04658173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*